Evidence map›Paper›PMID 26666289›Full record

ArticleBMC genomics2015

Leveraging global gene expression patterns to predict expression of unmeasured genes.

James Rudd, René A Zelaya, Eugene Demidenko, Ellen L Goode, Casey S Greene, Jennifer A Doherty

Abstract read
In one paragraph

Article in BMC genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

James RuddDepartment of Epidemiology, Geisel School of Medicine at Dartmouth College, One Medical Center Drive, 7927 Rubin Building, Lebanon, NH, 03756, USA. james.e.rudd.gr@dartmouth.edu.
René A ZelayaDepartment of Genetics, Geisel School of Medicine at Dartmouth College; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, 10-131 SCTR, 34th & Civic Center Boulevard, Philadelphia, PA, 19104-5158, USA. renearm@mail.med.upenn.edu.
Eugene DemidenkoDepartment of Biomedical Data Science, Geisel School of Medicine at Dartmouth College, One Medical Center Drive, 7927 Rubin Building, Lebanon, NH, 03756, USA. Eugene.Demidenko@Dartmouth.edu.
Ellen L GoodeDepartment of Health Sciences Research, Division of Epidemiology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. egoode@mayo.edu.
Casey S GreeneDepartment of Genetics, Geisel School of Medicine at Dartmouth College; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, 10-131 SCTR, 34th & Civic Center Boulevard, Philadelphia, PA, 19104-5158, USA. casey.s.greene@dartmouth.edu.
Jennifer A DohertyDepartment of Epidemiology, Geisel School of Medicine at Dartmouth College, One Medical Center Drive, 7927 Rubin Building, Lebanon, NH, 03756, USA. jennifer.a.doherty@dartmouth.edu.

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
Epidemiologic factors and survival by molecular subtypes of ovarian cancerR01CA168758 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DOHERTY, JENNIFER A., ROSSING, MARY ANNE · 2013 to 2016
$2.6M
Refining ovarian cancer subtype classifiers to incorporate biologic featuresF31CA186625 · NCI · DARTMOUTH COLLEGE · PI RUDD, JAMES · 2014 to 2016
$129k
NCI NIH HHS F31 CA186625NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA023108NCI NIH HHS P30 CA15083NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA168758
6 · The paper itself

Abstract

backgroundLarge collections of paraffin-embedded tissue represent a rich resource to test hypotheses based on gene expression patterns; however, measurement of genome-wide expression is cost-prohibitive on a large scale. Using the known expression correlation structure within a given disease type (in this case, high grade serous ovarian cancer; HGSC), we sought to identify reduced sets of directly measured (DM) genes which could accurately predict the expression of a maximized number of unmeasured genes.

resultsWe developed a greedy gene set selection (GGS) algorithm which returns a DM set of user specified size based on a specific correlation threshold (|rP|) and minimum number of DM genes that must be correlated to an unmeasured gene in order to infer the value of the unmeasured gene (redundancy). We evaluated GGS in the Cancer Genome Atlas (TCGA) HGSC data across 144 combinations of DM size, redundancy (1-3), and |rP| (0.60, 0.65, 0.70). Across the parameter sweep, GGS allows on average 9 times more gene expression information to be captured compared to the DM set alone. GGS successfully augments prognostic HGSC gene sets; the addition of 20 GGS selected genes more than doubles the number of genes whose expression is predictable. Moreover, the expression prediction is highly accurate. After training regression models for the predictable gene set using 2/3 of the TCGA data, the average accuracy (ranked correlation of true and predicted values) in the 1/3 testing partition and four independent populations is above 0.65 and approaches 0.8 for conservative parameter sets. We observe similar accuracies in the TCGA HGSC RNA-sequencing data. Specifically, the prediction accuracy increases with increasing redundancy and increasing |rP|.

conclusionsGGS-selected genes, which maximize expression information about unmeasured genes, can be combined with candidate gene sets as a cost effective way to increase the amount of gene expression information obtained in large studies. This method can be applied to any organism, model system, disease, or tissue type for which whole genome gene expression data exists.

Indexed as

Gene ExpressionAlgorithmsComputational BiologyDatabases, GeneticGene Expression Regulation, NeoplasticHumansNeoplasmsRegression AnalysisSequence Analysis, RNA

Identifiers

PMID26666289
PMCPMC4678722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.